Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Neoadjuvant Chemoradiotherapy for GEJ Adenocarcinoma
NCT03986385Phase 3Unknown
- Sponsor
- Hebei Medical University
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in adenocarcinoma of the gastroesophageal junction, sponsored by Hebei Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT03986385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03986385.